Design Strategy of PepNzymes-SH for an Emerging Catalyst with Serine Hydrolase-Like Functionality
ACS Applied Materials & Interfaces · 2025
DOI: 10.1021/acsami.4c19978 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift ACS Applied Materials & Interfaces, 2025. Verfasst von Yunfei Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory of Biobased Materials, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, Qingdao 266101, Chin…. Hauptthemen laut MEDLINE: Hydrolases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 139 Literaturangaben. Gefördert von: Taishan Scholar Project of Shandong Province.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CAS Key Laboratory of Biobased Materials, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, Qingdao 266101, China.
- Shandong Energy Institute, Qingdao 266101, China.
- Qingdao New Energy Shandong Laboratory, Qingdao 266101, China.
- University of Chinese Academy of Sciences, Beijing 101408, China.
Förderung
- Taishan Scholar Project of Shandong Province
Zitieren
APA
Li, Y., Jiang, L., Liu, Y., Lin, Y., Li, S., Xu, C., & Xian, M. (2025). Design Strategy of PepNzymes-SH for an Emerging Catalyst with Serine Hydrolase-Like Functionality. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c19978
Vancouver
Li Y, Jiang L, Liu Y, Lin Y, Li S, Xu C, et al. Design Strategy of PepNzymes-SH for an Emerging Catalyst with Serine Hydrolase-Like Functionality. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.4c19978
BibTeX
@article{Li2025,
author = {Li, Yunfei and Jiang, Long and Liu, Yaojie and Lin, Yu and Li, Shuhua and Xu, Chao and Xian, Mo},
title = {Design Strategy of PepNzymes-SH for an Emerging Catalyst with Serine Hydrolase-Like Functionality},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
doi = {10.1021/acsami.4c19978}
}
EUVIMED